SCHEDULE 13D
Item 1. | Security and Issuer |
This Amendment No. 4 (“Amendment No. 4”) supplements and amends the Schedule 13D relating to shares of common stock, par value $0.0001 per share (the “Common Stock”), of RAPT Therapeutics, Inc., a Delaware corporation (the “Issuer”) that was filed with the Securities and Exchange Commission (the “SEC”) on November 8, 2019 as it was amended by Amendment No. 1 thereto filed with the SEC on February 14, 2020, Amendment No. 2 thereto filed with the SEC on August 26, 2020 and Amendment No. 3 thereto filed with the SEC on October 1, 2020 (collectively, the “Amended Statement”). Only those items that are reported are hereby amended; all other items reported in the Amended Statement remain unchanged. Capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Amended Statement. Information given in response to each item shall be deemed incorporated by reference in all other items as applicable.
Item 5. | Interest in Securities of the Issuer |
Solely on behalf of, and only to the extent that it relates to the Reporting Persons, Item 5 of the Original 13D is hereby amended as follows:
(a) and (b) See Items 7-11 of the cover pages of this Amendment No. 4.
(c) On August 18, 2021, TCG II LP effected a pro rata distribution without additional consideration of 1,317,005 shares of Common Stock to (i) TCG II GP LP, its general partner and (ii) its limited partners. TCG II GP LP then effected a pro rata distribution without additional consideration of the shares that it received in connection with such distribution to its members (the “Distribution”).
On August 18, 2021, TCG LLC received 91 shares in the Distribution.
On August 18, 2021, Peter Svennilson received 64,425 shares in the Distribution.
On August 18, 2021, David V. Goeddel received 64,425 shares in the Distribution.
On August 18, 2021, Timothy Kutzkey received 35,746 shares in the Distribution.
On August 20, 2021, Peter Svennilson sold 1,440 Common Shares at a weighted average price per share of $30.0879 for aggregate proceeds of approximately $43,326.58.
On August 20, 2021, David V. Goeddel sold 1,429 Common Shares at a weighted average price per share of $30.0802 for aggregate proceeds of approximately $42,984.61.
On August 20, 2021, Timothy Kutzkey sold 1,670 Common Shares at a weighted average price per share of $30.0732 for aggregate proceeds of approximately $50,222.24.
On August 23, 2021, Peter Svennilson sold 7,605 Common Shares at a weighted average price per share of $30.9267 for aggregate proceeds of approximately $235,197.55.
On August 23, 2021, Peter Svennilson sold 12,969 Common Shares at a weighted average price per share of $31.4113 for aggregate proceeds of approximately $407,373.15.
On August 23, 2021, Peter Svennilson sold 2,200 Common Shares at a weighted average price per share of $32.3490 for aggregate proceeds of approximately $71,167.80.
On August 23, 2021, David V. Goeddel sold 7,278 Common Shares at a weighted average price per share of $30.9187 for aggregate proceeds of approximately $225,026.30.